San Clemente, California – March 25, 2016 – Sovereign Health has released a new article focused on the ongoing debate about Probuphine, a subdermal implant for the treatment of opioid addiction. As noted in the piece, “Political debate leaves opioid implant hanging in the balance,” Braeburn Pharmaceuticals – the creator of Probuphine – announced that it’s still moving forward and investing $20 million to plant a research and development manufacturing site in Durham, North Carolina. This follows a recent volley of developments regarding opioid treatment. To read the full story, click HERE.
“This editorial series takes a look at the current state of opioid addiction treatment in the U.S. and the continued debate surrounding the implant,” said Rachael Mattice, managing editor for the Sovereign Health Group. “The FDA reportedly put off giving its ruling on the twice-proposed implant, until 90 days after its original action date. Sovereign Health Group will follow this story as it unfolds so we can continue to report on the latest behavioral health news for our readers.”
This article is the third of a three-part series on the opioid implant. The first article, “Inside the opioid addiction implant,” takes an in-depth look at the use of the implant to treat opioid dependency. The second piece, “FDA delays decision on Probuphine opioid implant,” focuses on the FDA’s role in the discussion.
To track this series, follow Sovereign Health on Facebook, LinkedIn or Twitter. Readers may also subscribe to Sovereign Health Group’s newsletter, a trusted source for news and developments on the topic of behavioral health. To read the March 2016 edition of the newsletter, click HERE. Sovereign Health will continue to educate professionals, patients and readers on subjects that affect the future of mental health and addiction treatment.
About the Sovereign Health Group
Sovereign Health Group’s mission has been to provide a broad spectrum of high-quality behavioral health treatment services. Sovereign Health’s treatment programs specialize in addressing underlying mental health conditions by utilizing innovative and cutting edge cognitive testing, rehabilitation and evidence-based treatment modalities. One factor that differentiates Sovereign from other treatment providers has been the company’s ability to offer separate mental health and addiction or dual diagnosis treatment programs at its nine facilities in Arizona, California, Florida, Utah, and Texas. Sovereign’s growth will continue in the coming year with additional facilities to be opened in California and Texas. The company’s national footprint will also expand with the opening of facilities in Massachusetts, New Jersey, Pennsylvania and Illinois. Sovereign Health Group offers high quality and comprehensive treatment programs for adults and adolescents, including support services for family members as well.
To learn more about Sovereign Health Group and its wide range of services, please contact Wendy Allen, Public Relations Manager, at 866-686-0090 or visit www.sovhealth.com